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Abstract Alzheimer’s disease (AD) is a neurodegenerative
disorder whose hallmark is the presence of senile plaques and
neurofibrillary tangles. Senile plaques are mainly composed of
amyloid L-peptide (AL) fibrils and several proteins including
acetylcholinesterase (AChE). AChE has been previously shown
to stimulate the aggregation of AL1ÿ40 into amyloid fibrils. In the
present work, the neurotoxicity of different amyloid aggregates
formed in the absence or presence of AChE was evaluated in rat
pheochromocytoma PC12 cells. Stable AChE-AL complexes
were found to be more toxic than those formed without the
enzyme, for AL1ÿ40 and AL1ÿ42, but not for amyloid fibrils
formed with ALVal18!Ala, a synthetic variant of the AL1ÿ40
peptide. Of all the AChE-AL complexes tested the one containing
the AL1ÿ40 peptide was the most toxic. When increasing
concentrations of AChE were used to aggregate the AL1ÿ40
peptide, the neurotoxicity of the complexes increased as a
function of the amount of enzyme bound to each complex. Our
results show that AChE-AL1ÿ40 aggregates are more toxic than
those of AChE-AL1ÿ42 and that the neurotoxicity depends on the
amount of AChE bound to the complexes, suggesting that AChE
may play a key role in the neurodegeneration observed in
Alzheimer brain.
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Alzheimer’s disease (AD) is characterized by a selective
neuronal degeneration, intracellular accumulation of neuro¢-
brillary tangles and extracellular local deposits of amyloid in
the form of senile plaques [1,2]. Senile plaques are mainly
composed of an amyloid L-peptide (AL) of 40^43 amino acids
[3] which is neurotoxic when it forms amyloid ¢brils in vitro
[4] and in vivo [5], although this by itself cannot explain the
cascade of events which underlies this disease [6]. In fact, the
presence of senile plaques in the brains of individuals without
AD symptoms [7] suggests that speci¢c agents could trans-
form innocuous plaques into neuropathogenic aggregates.
The factors that contribute to the putative transformation
of the AL amyloid from a relatively inert to a pathogenic state
remain unknown and may involve interactions with additional
plaque constituents. Several macromolecules have been re-
ported to be associated with senile plaques including apolipo-
protein E, K1-antichymotrypsin, K2-macroglobulin, perlecan,
laminin, complement factors and acetylcholinesterase (AChE)
[8^11]. Nonetheless, the role of these molecules in the develop-
ment of AD is unknown.
AChE, the enzyme which catalyzes the hydrolysis of the
neurotransmitter acetylcholine [12], has been implicated in
di¡erent non-cholinergic activities [13] including a possible
role in the development of AD [14,15]. AChE has been found
to co-localize with AL in mature senile plaques and cerebral
blood vessels [16]. Moreover, most of the brain areas which
are susceptible to plaque formation are strongly AChE pos-
itive [17]. In our laboratory, the ability of various AChE mo-
lecular forms to promote the aggregation of AL1ÿ40 was dem-
onstrated in vitro [9]. Furthermore, the presence of AChE in
the AL1ÿ40 pre-formed ¢brils renders the amyloid ¢brils more
toxic [18,19].
Considering that senile plaques are mainly composed of
AL1ÿ40 and AL1ÿ42 [2,11,20], the aim of the present work
was to evaluate the relative contribution of AChE to the
neurotoxicity of amyloid ¢brils formed with di¡erent AL pep-
tides, and to establish whether the potential di¡erence in tox-
icity is induced by changes in the AChE concentration in the
enzyme-AL complexes.
2. Materials and methods
2.1. Materials
Synthetic AL peptides corresponding to residues of the human wild-
type sequence AL1ÿ40 and AL1ÿ42, as well as a variant AL1ÿ40 peptide
containing a valine to alanine substitution ALVal18!Ala with a very low
¢brillogenetic capacity [21], were used in the present work. All the
peptides were puri¢ed by HPLC and obtained from Chiron Corp. Inc.
(Emeryville, CA, USA).
2.2. AChE puri¢cation
The tetrameric G4 AChE form (sedimentation coe⁄cient 10.7 S)
was puri¢ed from bovine caudate nucleus, using acridine-a⁄nity chro-
matography as described previously [22]. Both speci¢c activities (6000
U/mg protein) and staining intensities following SDS-polyacrylamide
gel electrophoresis (PAGE) (a single band of 66 kDa) were used to
verify purity. AChE activity was determined by the method of Ellman
et al. [23].
2.3. Aggregation assays
2.3.1. Turbidity. The aggregation assay was carried out as previ-
ously described [10,18]. Speci¢cally, stock solutions were prepared by
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dissolving freeze-dried aliquots of AL1ÿ40, AL1ÿ42 and ALVal18!Ala in
dimethyl sulfoxide (DMSO) at 15 Wg/ml (3.5 mM). Aliquots of pep-
tide stock (70 nmol in 20 Wl of DMSO) were added to aqueous bu¡er
(725 Wl total volume; 0.1 M Tris-HCl, pH 7.4). In order to avoid
initial aggregation an ‘alkaline shock’ was induced by 2.5 N NaOH
up to 8.5 pH and neutralized by 2.5 N HCl down to 7.2 pH. For the
aggregation assays with AChE, peptide stock (70 nmol in DMSO) was
added to bu¡er containing AChE (100 nM). The solutions were
stirred continuously (210 rpm) at room temperature for 48 h. Aggre-
gation was measured by turbidity at 405 nm vs. bu¡er blank. In a
second series of experiments, AL1ÿ40 was induced to aggregate in the
same conditions with increasing concentrations of AChE (25, 100 and
250 nM). The ¢brils obtained were characterized by Congo red (CR)
binding and thio£avine-t (Th-t) based £uorometric assays.
2.3.2. Th-t based £uorometric assay. Th-t binds speci¢cally to L-
pleated structures such as amyloid and this binding produces a shift in
its emission spectrum and £uorescent signal related to the amount of
amyloid formed [24]. Fibril aliquots (3 Wl) from the aggregation assays
were added to 50 mM phosphate (pH 6.0) and 3 WM Th-t to a ¢nal
volume of 500 Wl [25]. A £uorescence time scan was performed and
£uorescence was monitored at excitation 450 nm and emission 485 nm
using a Shimadzu spectro£uorometer. For co-incubation experiments
the £uorescence of AChE alone was determined as a blank, giving
values of 2 or less.
2.3.3. CR assay. The binding of CR to amyloid ¢brils was used to
quantify the amount of ¢brils in an aggregation assay [26]. Fibril
aliquots (40 Wl) were added to 960 Wl of a solution containing 25
WM CR, 100 mM phosphate bu¡er (pH 7.4) and 150 mM NaCl,
and incubated for 30 min [18]. Absorbance was measured at 480
nm and 540 nm, and CR binding was determined by CR
(M) = (A540/25 295)3(A480/46 306).
2.4. Amyloid ¢bril isolation
Pre-formed ¢brils were washed four times with phosphate bu¡ered
saline (PBS) at 14 000 rpm for 30 min to remove the soluble AL and
AChE [18,25]. Pellets were homogenized in PBS. Aliquots were put on
a denaturing bu¡er and subjected to Tris-Tricine SDS-PAGE [27] to
quantify the concentrations of AL peptide contained in the ¢brils by
densitometric scanning using AL and AChE with known concentra-
tions as controls. Data were processed by the GS365W program from
Hoefer Scienti¢c Instruments (San Francisco, CA, USA).
2.5. Identi¢cation of AChE in the complexes
The presence of AChE in the complexes was identi¢ed using a
modi¢ed histochemical method [28], as previously described [18,25].
Brie£y, AChE-AL complexes were incubated in a solution (pH 6.0)
containing acetylthiocholine iodide as an enzymatic substrate for 30
min at room temperature in the presence of 0.1 mM iso-OMPA (bu-
tyrylcholinesterase speci¢c inhibitor). AChE activity produced a char-
acteristic brown stain which was visualized under a light microscope.
2.6. Cytotoxicity assays
Rat pheochromocytoma (PC12) cells [29] were grown on collagen
coated dishes in Dulbecco’s modi¢ed Eagle’s medium, 10% fetal calf
serum, 5% horse serum and 100 U/ml penicillin and 100 mg/ml strep-
tomycin. Cytotoxicity assays were performed as previously described
[19,30,31]. Cells were dissociated using a Pasteur pipette and washed
with serum-free medium for 10 min at 1500 rpm. Cells were seeded in
96 well plates in serum-free medium with 2 WM insulin at a density of
4U103 cells/100 Wl/well [32]. 10 Wl PBS (control), ¢brils and AChE-AL
complexes were added to reach a ¢nal concentration of 1, 10 or 25
WM AL peptide. Cells were incubated for 48 hours at 37‡C, after
which cell viability was measured by the 3-(4,5-dimethylthiazol-2-yl)-
Fig. 1. Histochemical staining of AChE bound to amyloid ¢brils. Amyloid ¢brils containing AChE from aggregation assays with AL1ÿ40 (A),
AL1ÿ42 (B) and ALVal18!Ala (C) were washed three times with PBS and stained by the Karnovsky and Roots method [28]. The ¢brils containing
AL1ÿ40 (or the other peptides) alone did not present AChE activity (D). Photographs were taken with a Nikon Optiphot light microscope at
600U magni¢cation.
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2,5-diphenyltetrazolium bromide (MTT) method [33] by adding 11 Wl
MTT stock (5 mg/ml). The reaction was stopped 4 h later by adding
110 Wl stop solution (50% dimethylformamide and 20% SDS at pH
4.7). MTT reduction was determined in a Labsystems Uniskam I
spectrophotometer (Finland) at 540 and 650 nm. Identical experi-
ments were performed with 10 WM ¢brils and complexes and were
followed by lactic dehydrogenase (LDH) release test using the Cyto-
tox 96 kit from Promega (Madison, WI, USA), as previously de-
scribed [30,31].
3. Results
3.1. AChE is present on amyloid ¢bril complexes formed with
di¡erent AL peptides
The presence of AChE in amyloid ¢brils formed with the
peptides AL1ÿ40, AL1ÿ42 and AL Val18!Ala was evidenced his-
tochemically by the method of Karnovsky and Roots [28].
Fig. 1 shows positive stains for AChE activity in all three
cases. The ¢brils obtained for AL1ÿ40 and AL1ÿ42 form large
compact aggregates (Fig. 1A,B), while ALVal18!Ala produced
smaller and more disperse ¢brils (Fig. 1C). No staining was
observed for AL1ÿ40 ¢brils pre-formed without AChE (Fig.
1D), and for AL1ÿ42 and ALVal18!Ala alone (data not shown).
3.2. Cytotoxicity of AChE-AL complexes depends on the type
of AL peptides
To evaluate whether AChE-AL complexes formed from dif-
ferent AL peptides (AL1ÿ40, AL1ÿ42 and ALVal18!Ala) play a
role in cell damage, the e¡ect of exogenously applied com-
plexes on rat pheochromocytoma PC12 cells was examined.
Neurotoxicity was evaluated using the MTT reduction assay,
an indicator of cell redox activity [30,33,31]. The experiments
were carried out using 100 nM AChE to form the complexes,
which were processed as described in Section 2. Final concen-
trations per well of 1, 10 and 25 WM AL peptide, both in the
¢brils and in the complexes, were used [18,19]. For 10 and 25
WM AL1ÿ40 and AL1ÿ42, the ¢brils containing AChE were
more toxic than those without the enzyme (Fig. 2A,B). For
instance, at a concentration of 25 WM AL1ÿ40 ¢brils with
AChE were two-fold more toxic than AL1ÿ40 ¢brils alone.
The highest cytotoxicity in either the presence or absence of
AChE was obtained with the AL1ÿ40 peptide. On the other
hand, ALVal18!Ala ¢brils, formed by a peptide with low ¢bril-
logenetic capacity [21], showed almost no toxicity, in either
the presence or absence of AChE (Fig. 2C).
3.3. Cytotoxicity depends on the concentrations of AChE bound
to the ¢brils
Considering that AL1ÿ40 ¢brils were found to be more toxic
than the other AL peptides tested, this peptide was used to
assess the AChE concentration dependence of the cytotoxicity
observed with the AChE-AL complex. AL1ÿ40 peptide was
incubated with di¡erent AChE concentrations (25, 100 and
250 nM) and ¢bril formation was followed by turbidity.
Fig. 3A shows that the aggregation of the AL1ÿ40 peptide
increased as a function of AChE concentration. In order to
verify that the ¢brils formed corresponded to amyloid, Th-t
£uorescence (Fig. 3B) and CR binding (Fig. 3C) assays were
carried out. In both cases, the quantity of amyloid increased
as a function of the AChE concentration. SDS-PAGE was
carried out to demonstrate the presence of AChE in the amy-
loid ¢brils. As expected, increasing amounts of AChE bound
to the AL ¢brils were observed by SDS-PAGE, and the AChE
Fig. 2. Inhibition of MTT reduction in PC12 cells after 48 h of
treatment with three concentrations of pre-formed ¢brils (1, 10 and
25 WM) with and without AChE. The di¡erent peptides were AL1ÿ40
(A), AL1ÿ42 (B) and AL Val18!Ala (C). MTT reduction assay values
were expressed as percentage of control values. Data are means
þ S.E.M. (bars) of 6^9 separate experiments performed in triplicate.
*P6 0.05; **P6 0.005 by non-paired Student’s t-test. The AChE
bound to ¢brils was determined by SDS-PAGE gels and corre-
sponds to 7.5, 10 and 25 nM AChE bound to 1, 10 and 25 WM
AL1ÿ40 and AL1ÿ42. The inset shows the MTT reduction percentages
obtained with AChE alone, data are means þ S.E.M. (bars) of six
separate experiments performed in triplicate. *P6 0.05 by non-
paired Student’s t-test.
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amount was proportional to the initial concentration of
AChE used in each case (Fig. 3D). Finally, when AL ¢brils
(25 WM) formed in the presence of di¡erent concentrations of
AChE were used for cytotoxicity assays, ¢bril toxicity was
found to increase in relation to the amount of AChE bound
to the ¢brils (Fig. 4). Fibrils incubated with the highest con-
centration of AChE were the most cytotoxic, whereas no dif-
ference was observed between ¢brils without AChE and those
pre-formed with a low amount of AChE. In order to verify
the observed di¡erence in the neurotoxicity induced by the
AChE-AL complexes respect to AL ¢brils, LDH release test
was carried out, as indicated in the inset of Fig. 4, and similar
results to those obtained with the MTT reduction assay were
observed with this test.
4. Discussion
Previous studies in our laboratory have shown that AChE
accelerated the assembly of the AL1ÿ40 peptide into amyloid
¢brils, through the formation of a stable AChE-AL complex
which turns amyloid ¢brils more toxic [9,18,19]. In the present
work we have found that AL1ÿ42 peptide increases its neuro-
toxicity when it forms aggregates with AChE, and the cyto-
toxicity produced by AChE-AL1ÿ40 complexes depends on the
concentration of enzyme bound to the complex, those com-
plexes which contain higher amounts of AChE being more
toxic.
Considering that the presence of senile plaques in the brain
of aging individuals does not necessarily lead to symptoms of
AD [7], the presence of AChE in some critically located senile
plaques could play a key role in triggering the cytotoxic events
which occur around mature plaques in AD. AL1ÿ42 has been
suggested to be important for inducing AL deposits
[2,11,34,35]. Fibril formation has been suggested to be impor-
tant for AL cytotoxicity [36], and previous studies have found
that once formed, aggregates of AL1ÿ42 and AL1ÿ40 appear to
be equally neurotoxic [37]. We have obtained the highest cy-
totoxicity in either the presence or absence of AChE with the
AL1ÿ40 peptide, although AL1ÿ42 showed a high cytotoxicity
on PC12 cells with AL ¢brils alone or with AChE complexes.
AChE seems to act by an enhancement of the ¢bril toxicity,
but not by converting low- or non-toxic peptides into toxic
ones, as was the case for the synthetic variant ALVal18!Ala.
AChE has been found to be associated with AL deposits
from the beginning of plaque formation. In fact both pre-
amyloid di¡use deposits as well as compact senile plaques
contain the enzyme [38]. Moreover, AChE forms very stable
enzyme-AL complexes in vitro and remains tightly bound to
AL aggregates after washing them with high salt solutions and
detergents [25]. These results indicate that AChE may partic-
ipate by providing heterogeneous nuclei during the seeding
and growth phase of amyloid ¢brils [18,39].
In conclusion, extensive evidence has accumulated indicat-
ing that AL aggregation into amyloid deposits is a central
event in the pathogenesis of AD [2,4]. Our present ¢ndings
indicate that AChE was able to modulate the AL aggregation
into Alzheimer ¢brils, and to increase the neurotoxicity of the
AChE-AL complexes towards neuronal cells in culture, de-
spite the fact that AChE, by itself, was not able to render
inert peptides toxic.
Fig. 3. E¡ect of increasing concentrations of AChE (25, 100 and 250 nM) on the formation of AL1ÿ40 ¢brils by using 70 nmol AL1ÿ40. AChE-
AL complexes were obtained after turbidity experiments (A) up to 300 min when the di¡erent aggregation kinetics reached a plateau. At the
end of the assays (24 h), aliquots were taken to quantify amyloid by Th-t £uorescence (B) and CR binding (C). Data are from a representative
experiment of three separate ones performed. D shows a SDS-PAGE with samples from the aggregation assays which were washed three times
to remove all the soluble components of AL1ÿ40 aggregates incubated with and without increasing concentrations of AChE. An increasing
amount of AChE was bound to the ¢brils depending on the initial concentration of AChE. The di¡erent lanes were occupied as follows: lane
1, 10 Wl of puri¢ed AL1ÿ40 ¢brils; lanes 2, 3 and 4, with 10 Wl of puri¢ed AChE-AL1ÿ40 ¢brils aggregated with 25, 100 and 250 nM AChE re-
spectively.
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Fig. 4. E¡ects of ¢brils with increasing concentrations of AChE on
MTT reduction in PC12 cells. Cells were incubated with 25 WM ¢-
brils without or with AChE for 48 h. Control values with PBS were
taken as 100%. Data are means þ S.E.M. (bars) of ¢ve di¡erent ex-
periments performed in triplicate. ns: not statistically di¡erent;
*P6 0.05; **P6 0.005 by non-paired Student’s t-test. AChE bound
to 25 WM AL1ÿ40 was 7.5, 25 and 50 nM when 25, 100 and 250 nM
AChE, respectively, were used in the incubations. Inset A shows the
e¡ect of AChE alone on MTT reduction and data are means
þ S.E.M. (bars) of six di¡erent experiments performed in triplicate.
*P6 0.05; **P6 0.005. Inset B shows the e¡ect of 10 WM AL1ÿ40
¢brils and AChE-AL complexes (having incubated the peptide with
100 nM AChE) on LDH release, total released enzyme was taken
as 100%. Data are means þ S.E.M. (bars) of three di¡erent experi-
ments performed in triplicate. *P6 0.05; **P6 0.005.
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